Research use only: what the label means and where regulators stand
What 'research use only' actually means, and how the FDA's position on peptides and unapproved GLP-1s frames it.
What 'research use only' actually means, and how the FDA's position on peptides and unapproved GLP-1s frames it.

"Research use only" is a label with a specific meaning, and it is worth stating plainly because it is often read as a euphemism rather than a category. Materials marked research use only are not approved for human or veterinary use. They are produced and sold for research purposes — for study, for characterization, for laboratory work — and not for administration to people or animals. That is not a loophole; it is a category, and it carries the obligation not to blur it.
The regulatory backdrop makes the category concrete. The FDA's 503A category 2 list, which in September 2023 placed BPC-157 among bulk drug substances that may present significant safety risks, is a statement that certain peptides are not cleared for the routes people sometimes attempt, and that the reasons are impurity profiling and identity characterization — the hard parts of making a peptide reproducible and safe. A 2024 FDA advisory committee presentation reinforced the mechanism, explaining that peptide impurities, including aggregates, can raise immunogenicity risk, up to life-threatening reactions. And the FDA's warnings about fraudulent and unapproved GLP-1 products — compounded semaglutide and tirzepatide with false labels, salt forms that are different active ingredients, and adverse event reports including hospitalizations — are a direct example of what happens when research or unapproved materials cross into use they were not characterized for.
What this means for a buyer is narrow and practical. A research-use-only material should be treated as a material to be tested and understood, not as a finished product to be used. The right questions are the testing questions: is it the molecule the label names (identity), how pure is it (purity), how much is actually in the vial (content), and does it carry endotoxin or other safety-relevant contaminants. A certificate of analysis answers those questions on the actual sample. It does not convert a research material into an approved one — nothing does that except the regulatory process — but it does tell you what you have, which is the prerequisite for any responsible research use.
Two things this is not. It is not medical advice, and it is not legal advice. Whether a given material may be possessed, sold, or used in a particular jurisdiction is a legal question for someone qualified to answer it. What a testing lab can do — and what we do — is report what is in the vial, accurately and verifiably, so that the research decision starts from a result instead of a label. That is the boundary the research-use-only label draws, and it is the boundary we work within.
Nothing here is intended for human or veterinary use; that remains true of the materials, and it remains true of this article.
Cites: FDA 503A category 2 list (2023); FDA PCAC (2024); FDA GLP-1 concerns.
Regulator2023In September 2023 the FDA placed BPC-157 on its list of bulk drug substances that may present significant safety risks for compounding.
Regulator2026The FDA has warned about fraudulent and unapproved compounded GLP-1 products, including false labels and dosing-error adverse events.